Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118406) titled 'Prospective Phase II Clinical Study of Neoadjuvant Therapy with Disitamab Vedotin Combined with Radiotherapy, Sintilimab, and Capecitabine for HER2-Overexpressing Locally Advanced Gastric Cancer' on Feb. 5.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Jiangsu Cancer Hospital
Condition:
Gastric Cancer
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2025-12-19
Target Sample Size: Intervention Group:35;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=286620
Published by HT Digital Content Services with pe...